2013 Q2 Form 10-Q Financial Statement

#000110465913041980 Filed on May 15, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2013 Q1 2012 Q1
Revenue $281.0K $147.0K $208.0K
YoY Change 208.79% -29.33%
Cost Of Revenue $0.00
YoY Change
Gross Profit $100.0K
YoY Change
Gross Profit Margin 68.03%
Selling, General & Admin $12.20M $13.53M $2.728M
YoY Change 165.22% 396.08% 60.47%
% of Gross Profit 13533.0%
Research & Development $3.500M $4.522M $5.358M
YoY Change -25.53% -15.6% -28.09%
% of Gross Profit 4522.0%
Depreciation & Amortization $100.0K $162.0K $225.0K
YoY Change -35.9% -28.0% 12.5%
% of Gross Profit 162.0%
Operating Expenses $15.70M $18.06M $8.086M
YoY Change 68.82% 123.29% 8.52%
Operating Profit -$17.91M -$7.878M
YoY Change 127.32% -14.35%
Interest Expense -$10.70M $727.0K $962.0K
YoY Change 970.0% -24.43% -420.67%
% of Operating Profit
Other Income/Expense, Net $0.00 -$506.0K -$1.399M
YoY Change -100.0% -63.83% 599.5%
Pretax Income -$27.40M -$18.40M -$9.300M
YoY Change 174.0% 97.85% -4.12%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$27.36M -$18.41M -$9.277M
YoY Change 173.21% 98.49% -16.04%
Net Earnings / Revenue -9735.59% -12526.53% -4460.1%
Basic Earnings Per Share
Diluted Earnings Per Share -$886.7K -$595.5K -$715.4K
COMMON SHARES
Basic Shares Outstanding 30.99M shares 30.89M shares 1.676M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q2 2013 Q1 2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $102.6M $69.90M $37.40M
YoY Change 34.29% 86.9%
Cash & Equivalents $33.90M $18.91M $15.87M
Short-Term Investments $68.70M $51.00M $21.50M
Other Short-Term Assets $2.300M $1.000M $1.000M
YoY Change 64.29% 0.0%
Inventory $4.300M $3.113M
Prepaid Expenses
Receivables $500.0K $1.650M
Other Receivables $800.0K $600.0K
Total Short-Term Assets $110.6M $76.33M $38.42M
YoY Change 42.15% 98.69%
LONG-TERM ASSETS
Property, Plant & Equipment $2.200M $1.687M $1.200M
YoY Change 91.97% 40.58%
Goodwill
YoY Change
Intangibles $626.0K
YoY Change
Long-Term Investments $16.10M
YoY Change
Other Assets $2.500M $363.0K $2.700M
YoY Change 1150.0% -86.56%
Total Long-Term Assets $21.40M $2.729M $4.785M
YoY Change 890.74% -42.97%
TOTAL ASSETS
Total Short-Term Assets $110.6M $76.33M $38.42M
Total Long-Term Assets $21.40M $2.729M $4.785M
Total Assets $132.0M $79.06M $43.20M
YoY Change 65.07% 83.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.200M $3.700M $9.300M
YoY Change -76.09% -60.22%
Accrued Expenses $9.600M $7.240M $1.200M
YoY Change 500.0% 503.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $12.10M $9.200M
YoY Change -100.0% 31.52%
Total Short-Term Liabilities $16.00M $27.01M $19.91M
YoY Change -26.88% 35.64%
LONG-TERM LIABILITIES
Long-Term Debt $59.10M $8.000M $19.90M
YoY Change 245.61% -59.8%
Other Long-Term Liabilities $21.00M $1.860M $3.100M
YoY Change 600.0% -40.0%
Total Long-Term Liabilities $80.10M $1.860M $23.00M
YoY Change 298.51% -91.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.00M $27.01M $19.91M
Total Long-Term Liabilities $80.10M $1.860M $23.00M
Total Liabilities $96.10M $37.79M $42.93M
YoY Change 128.89% -11.97%
SHAREHOLDERS EQUITY
Retained Earnings -$104.7M
YoY Change
Common Stock $31.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $35.90M $41.27M $274.0K
YoY Change
Total Liabilities & Shareholders Equity $132.0M $79.06M $43.20M
YoY Change 65.0% 83.0%

Cashflow Statement

Concept 2013 Q2 2013 Q1 2012 Q1
OPERATING ACTIVITIES
Net Income -$27.36M -$18.41M -$9.277M
YoY Change 173.21% 98.49% -16.04%
Depreciation, Depletion And Amortization $100.0K $162.0K $225.0K
YoY Change -35.9% -28.0% 12.5%
Cash From Operating Activities -$15.80M -$17.22M -$10.07M
YoY Change 62.89% 71.07% 2.73%
INVESTING ACTIVITIES
Capital Expenditures -$600.0K $372.0K $40.00K
YoY Change 200.0% 830.0% -120.0%
Acquisitions
YoY Change
Other Investing Activities -$33.80M -$2.800M -$21.50M
YoY Change 338.96% -86.98% 290.91%
Cash From Investing Activities -$34.50M -$3.149M -$21.55M
YoY Change 348.05% -85.39% 278.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.936M $49.00K
YoY Change 3851.02%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 65.20M -$1.021M -$1.057M
YoY Change 33.33% -3.41% -108.39%
NET CHANGE
Cash From Operating Activities -15.80M -$17.22M -$10.07M
Cash From Investing Activities -34.50M -$3.149M -$21.55M
Cash From Financing Activities 65.20M -$1.021M -$1.057M
Net Change In Cash 14.90M -$21.39M -$32.68M
YoY Change -52.7% -34.53% 1026.83%
FREE CASH FLOW
Cash From Operating Activities -$15.80M -$17.22M -$10.07M
Capital Expenditures -$600.0K $372.0K $40.00K
Free Cash Flow -$15.20M -$17.60M -$10.11M
YoY Change 60.0% 74.07% 5.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40302000 USD
CY2012Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
48206000 USD
CY2013Q1 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P10Y
CY2012Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
664000 USD
CY2012Q4 us-gaap Inventory Net
InventoryNet
1152000 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
994000 USD
CY2012Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
144000 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
91462000 USD
CY2013Q1 us-gaap Assets Current
AssetsCurrent
76332000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1421000 USD
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
683000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
334000 USD
CY2012Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
89000 USD
CY2012Q4 us-gaap Assets
Assets
93989000 USD
CY2013Q1 us-gaap Assets
Assets
79061000 USD
CY2012Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10666000 USD
CY2012Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
11809000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22983000 USD
CY2013Q1 us-gaap Liabilities Current
LiabilitiesCurrent
27008000 USD
CY2012Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
11088000 USD
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1788000 USD
CY2012Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
251000 USD
CY2012Q4 us-gaap Liabilities
Liabilities
36419000 USD
CY2013Q1 us-gaap Liabilities
Liabilities
37789000 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
31000 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
143851000 USD
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-57000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-86255000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
57570000 USD
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
41272000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
93989000 USD
CY2013Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
79061000 USD
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2013Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2292000 USD
CY2013Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1666000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2292000 USD
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30894666 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30621869 shares
CY2013Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30894666 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30621869 shares
CY2012Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-328000 USD
CY2012Q1 us-gaap Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments
-8000 USD
CY2012Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
225000 USD
CY2012Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
83000 USD
CY2012Q1 us-gaap Share Based Compensation
ShareBasedCompensation
52000 USD
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1650000 USD
CY2013Q1 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
8000 USD
CY2013Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1961000 USD
CY2012Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10068000 USD
CY2012Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
158000 USD
CY2012Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1254000 USD
CY2012Q1 us-gaap Sales Revenue Net
SalesRevenueNet
208000 USD
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5358000 USD
CY2012Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2728000 USD
CY2012Q1 us-gaap Costs And Expenses
CostsAndExpenses
8086000 USD
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7878000 USD
CY2012Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
19000 USD
CY2012Q1 us-gaap Interest Expense
InterestExpense
962000 USD
CY2012Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-456000 USD
CY2012Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1399000 USD
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-9277000 USD
CY2012Q1 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
858000 USD
CY2012Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10135000 USD
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18414000 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-18414000 USD
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-506000 USD
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-17908000 USD
CY2013Q1 us-gaap Costs And Expenses
CostsAndExpenses
18055000 USD
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.60
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30875424 shares
CY2012Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-17000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17223000 USD
CY2012Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
21806000 USD
CY2012Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
293000 USD
CY2012Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
40000 USD
CY2012Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21553000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3149000 USD
CY2012Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
49000 USD
CY2012Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
437000 USD
CY2012Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
669000 USD
CY2012Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1057000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1021000 USD
CY2012Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-32678000 USD
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-21393000 USD
CY2012Q1 us-gaap Interest Paid
InterestPaid
688000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48544000 USD
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15866000 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18909000 USD
CY2013Q1 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1. Organization and Business</font></b></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Supernus Pharmaceuticals,&#160;Inc. (the Company) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company has two proprietary products and several proprietary product candidates in clinical development that address the epilepsy and attention deficit hyperactivity disorder markets.</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The Company is currently focused on the commercialization of Oxtellar&#160;XR and the anticipated commercialization of Trokendi&#160;XR (formerly known as SPN-538). Oxtellar&#160;XR received final approval from the Food and Drug Administration (FDA) on October&#160;19, 2012 and the Company began the commercial launch of this product on February&#160;4,&#160;2013.&#160; In addition, Trokendi&#160;XR received tentative approval from the FDA on June&#160;25,&#160;2012.&#160; The Company anticipates the commercial launch of this product in the third quarter of 2013 pending receipt of final approval from the FDA.</font></p> </div>
CY2013Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5184000 USD
CY2013Q1 dei Entity Registrant Name
EntityRegistrantName
SUPERNUS PHARMACEUTICALS INC
CY2013Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001356576
CY2013Q1 dei Document Type
DocumentType
10-Q
CY2013Q1 dei Document Period End Date
DocumentPeriodEndDate
2013-03-31
CY2013Q1 dei Amendment Flag
AmendmentFlag
false
CY2013Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30985416 shares
CY2013Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2013Q1 supn Number Of Proprietary Products In Clinical Development
NumberOfProprietaryProductsInClinicalDevelopment
2 item
CY2013Q1 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0 USD
CY2012Q1 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
150000 USD
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
48259000 USD
CY2012Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
1000 USD
CY2012Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
54000 USD
CY2012Q4 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
48206000 USD
CY2013Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
51072000 USD
CY2013Q1 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
0 USD
CY2013Q1 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
89000 USD
CY2013Q1 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
50983000 USD
CY2013Q1 us-gaap Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
2985000 USD
CY2012Q4 us-gaap Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
1152000 USD
CY2013Q1 supn Sales Return Period
SalesReturnPeriod
P1Y
CY2013Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
128000 USD
CY2013Q1 us-gaap Inventory Net
InventoryNet
3113000 USD
CY2013Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6871000 USD
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6499000 USD
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5078000 USD
CY2013Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1687000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1609000 USD
CY2012Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
57000 USD
CY2013Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
57000 USD
CY2013Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
626000 USD
CY2013Q1 supn Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
2898000 USD
CY2013Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2238000 USD
CY2013Q1 us-gaap Interest Payable Current
InterestPayableCurrent
187000 USD
CY2013Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1917000 USD
CY2013Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7240000 USD
CY2012Q4 supn Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
3335000 USD
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2492000 USD
CY2012Q4 us-gaap Interest Payable Current
InterestPayableCurrent
213000 USD
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1820000 USD
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7860000 USD
CY2012Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
8000 USD
CY2012Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9269000 USD
CY2013Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
363000 USD
CY2013Q1 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
53000 USD
CY2013Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10903000 USD
CY2013Q1 us-gaap Secured Debt Current
SecuredDebtCurrent
12137000 USD
CY2013Q1 us-gaap Secured Long Term Debt
SecuredLongTermDebt
7975000 USD
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18446000 USD
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1676442 shares
CY2013Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
50983000 USD
CY2013Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1650000 USD
CY2013Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
672000 USD
CY2013Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1860000 USD
CY2013Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
172000 USD
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
31000 USD
CY2013Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
145999000 USD
CY2013Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-89000 USD
CY2013Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104669000 USD
CY2013Q1 us-gaap Sales Revenue Net
SalesRevenueNet
147000 USD
CY2013Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
861000 USD
CY2013Q1 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
144000 USD
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4522000 USD
CY2013Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13533000 USD
CY2013Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
52000 USD
CY2013Q1 us-gaap Interest Expense
InterestExpense
727000 USD
CY2013Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
169000 USD
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.05
CY2013Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-32000. USD
CY2013Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-32000 USD
CY2012Q1 us-gaap Depreciation
Depreciation
167000 USD
CY2013Q1 us-gaap Depreciation
Depreciation
106000 USD
CY2012Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
8000 USD
CY2013Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
79000 USD
CY2013Q1 us-gaap Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments
32000 USD
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
162000 USD
CY2013Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
83000 USD
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
337000 USD
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-133000 USD
CY2013Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
238000 USD
CY2013Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
44000 USD
CY2013Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
15643000 USD
CY2013Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
12866000 USD
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
372000 USD
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1936000 USD
CY2013Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
2832000 USD
CY2013Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
125000 USD
CY2013Q1 us-gaap Interest Paid
InterestPaid
610000 USD
CY2012Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
52000 USD
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
337000 USD
CY2012 us-gaap Prior Period Reclassification Adjustment
PriorPeriodReclassificationAdjustment
279000 USD
CY2013Q1 supn Finite Lived Intangible Assets Estimated Annual Aggregate Amortization Expense
FiniteLivedIntangibleAssetsEstimatedAnnualAggregateAmortizationExpense
229000 USD
CY2012Q4 us-gaap Inventory Adjustments
InventoryAdjustments
0 USD
CY2013Q1 us-gaap Inventory Adjustments
InventoryAdjustments
0 USD
CY2013Q1 supn Inventory Work In Process And Raw Materials Net Of Reserves For Which Tentative Approval Received From Fda
InventoryWorkInProcessAndRawMaterialsNetOfReservesForWhichTentativeApprovalReceivedFromFDA
2000000 USD

Files In Submission

Name View Source Status
0001104659-13-041980-index-headers.html Edgar Link pending
0001104659-13-041980-index.html Edgar Link pending
0001104659-13-041980.txt Edgar Link pending
0001104659-13-041980-xbrl.zip Edgar Link pending
a13-8349_110q.htm Edgar Link pending
a13-8349_1ex31d1.htm Edgar Link pending
a13-8349_1ex31d2.htm Edgar Link pending
a13-8349_1ex32d1.htm Edgar Link pending
a13-8349_1ex32d2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
supn-20130331.xml Edgar Link completed
supn-20130331.xsd Edgar Link pending
supn-20130331_cal.xml Edgar Link unprocessable
supn-20130331_def.xml Edgar Link unprocessable
supn-20130331_lab.xml Edgar Link unprocessable
supn-20130331_pre.xml Edgar Link unprocessable